Sugi Predict

Sugi Predict / Compounds / SCHEMBL400625

SCHEMBL400625

SCHEMBL400625

Nc1ncnc2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)cn2[C@H]1CC[C@@H](CO)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 13/20 0.63
▸ RIPK2 O43353 2/20 0.59
▸ ABL1 P00519 9/20 0.58
▸ EGFR P00533 9/20 0.58
▸ ABL2 P42684 8/20 0.58
▸ LCK P06239 5/20 0.57
▸ KDR P35968 4/20 0.57
▸ LYN P07948 3/20 0.57
▸ JAK2 O60674 2/20 0.57
▸ NTRK1 P04629 2/20 0.57
▸ INSR P06213 2/20 0.57
▸ NPM1 P06748 2/20 0.57
▸ CSF1R P07333 2/20 0.57
▸ RET P07949 2/20 0.57
▸ IGF1R P08069 2/20 0.57
▸ MET P08581 2/20 0.57
▸ PDGFRB P09619 2/20 0.57
▸ KIT P10721 2/20 0.57
▸ BCR P11274 2/20 0.57
▸ FGFR1 P11362 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400624 1.00 SRC (0.63) SRCRIPK2ABL1EGFRABL2
SCHEMBL14193039 1.00 SRC (0.63) SRCRIPK2ABL1EGFRABL2
SCHEMBL396799 0.92 SRC (0.68) SRCRIPK2ABL1EGFRABL2
SCHEMBL402582 0.92 SRC (0.61) SRCRIPK2ABL1EGFRABL2
SCHEMBL396798 0.92 SRC (0.68) SRCRIPK2ABL1EGFRABL2
SCHEMBL13992401 0.92 SRC (0.68) SRCRIPK2ABL1EGFRABL2
SCHEMBL399403 0.89 SRC (0.71) SRCRIPK2ABL1EGFRABL2
SCHEMBL399498 0.87 SRC (0.59) SRCRIPK2ABL1EGFRABL2
Carbamic Acid SCHEMBL19244734 0.86 EGFR (0.64) SRCRIPK2ABL1EGFRABL2
SCHEMBL401691 0.85 ABL1 (0.72) SRCRIPK2ABL1EGFRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-8575164-B2 Combination cancer therapy OSI Pharmaceuticals, LLC (US) 2013-11-05 — — US disclosed
US-8575164-B2 Combination cancer therapy OSI Pharmaceuticals, LLC (US) 2013-11-05 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-12-04 — — US disclosed
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-12-04 — — US disclosed
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 — — US disclosed
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 — — US disclosed
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-01-17 — — US disclosed
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-01-17 — — US disclosed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 — — WO disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885RIPK2 784/4885ABL1 621/4885
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, IGFBP6, CDK6 SRC 292/4885RIPK2 604/4885ABL1 191/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885RIPK2 784/4885ABL1 621/4885
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, EGFR, ERBB2 SRC 35/4885RIPK2 942/4885ABL1 36/4885
US-20080267957-A1 Combination cancer therapy IGF1R, IGFBP4, IGFBP1 SRC 358/4885RIPK2 2010/4885ABL1 179/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885RIPK2 784/4885ABL1 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.